Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease

Anavex Life Sciences Corp. announced today that it has filed the regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

21 Dec 2010

ExonHit awarded QTDP grants for AclarusDx and EHT 107 programs

ExonHit Therapeutics today announced that the Company was awarded two grants to support two of its Research & Development projects under the Qualifying Therapeutic Discovery Project Program: AclarusDx™ in Alzheimer's disease and the EHT 107 program in oncology.

21 Dec 2010

Scientists boost protein supply to enhance muscle function, reduce nerve-dependent fatigue in mice

Researchers at Vanderbilt University have "engineered" a mouse that can run on a treadmill twice as long as a normal mouse by increasing its supply of acetylcholine, the neurotransmitter essential for muscle contraction.

21 Dec 2010

Biogen Idec acquires Neurimmune subsidiary

Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43.

21 Dec 2010

Lilly completes acquisition of Avid

Eli Lilly and Company today announced that it has completed the acquisition of Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and monitoring of chronic human diseases. The transaction, first announced on November 8, 2010, has received the approval of Avid stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. All other closing conditions have also been met.

20 Dec 2010

DNA tunneling detector embedded in a ‘Nanopore’

Scientists from Imperial College London are developing technology that could ultimately sequence a person's genome in mere minutes, at a fraction of the cost of current commercial techniques.

20 Dec 2010

BSI: Guidance is key to improve dementia care

Dementia is a critical health concern, but are the current care services able to offer appropriate support? Only a few days ago, the review by the Royal College of Psychiatrists found many dementia patients were not getting the support on nutrition and mental health that they should. The need for improved care is higher than ever.

20 Dec 2010

Proteins that unlock the mystery of over 100 brain diseases

An Anglo-American team of researchers have made a medical breakthrough after identifying a large collection of nerve proteins that are involved in around 130 brain diseases including Alzheimer’s and autism.

20 Dec 2010

Hyperpriming in early stages of Alzheimer's disease explained

The capacity to remember that a zebra has stripes, or that a giraffe is a four-legged mammal, is known as semantic memory. It allows us to assign meaning to words and to recall general knowledge and concepts that we have learned. The deterioration of these capacities is a defining feature of semantic dementia and can also occur in Alzheimer's disease.

20 Dec 2010

Comprehensive guidance for care providers on Dementia Care Mapping process

20 Dec 2010

DiaGenic issues notification of trade among insiders

On 17 December 2010 mandatory notification of trade among insiders of DiaGenic ASA took place.

20 Dec 2010

FVCG invests $175,000 in Celvive for stem cell research in spinal cord injury

Spinal cord injury (SCI) is a devastating neurological condition with limited therapeutic options. In the United States alone, there are more than 250,000 people living with SCI; approximately three million worldwide are affected.

20 Dec 2010

Diagenic, Pfizer enter collaboration to identify biomarkers in early stages of Alzheimer's disease

DiaGenic ASA and Pfizer Inc today signed an agreement for explorative R&D collaboration to identify biomarkers in early stages of Alzheimer's disease (AD) using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies.

17 Dec 2010

Alzheimer's Association applauds Congress for passage of NAPA Bill

As the leading care, research and advocacy organization for Alzheimer's disease, the Alzheimer's Association applauds Congress for passage of the National Alzheimer's Project Act (S. 3036, H.R. 4689), a significant step forward in the fight against Alzheimer's disease. The National Alzheimer's Project Act provides an essential framework for the development of a national strategic plan.

17 Dec 2010

Gene variant affects brain function long before brain begins accumulating amyloid: Study

People with a known, high risk for Alzheimer's disease develop abnormal brain function even before the appearance of telltale amyloid plaques that are characteristic of the disease, according to a new study.

17 Dec 2010

Mayo Clinic ACTS project supports African-American dementia caregivers

With a rapidly expanding population of elders, the number of dementia caregivers in Florida is increasing exponentially. According to the Alzheimer's Association, nearly 10 million caregivers provide unpaid care to people with Alzheimer's disease. Finding the best way to support caregivers, especially with fewer state resources available, is one focus of ongoing research at Mayo Clinic in Florida.

17 Dec 2010

Researchers discover new molecular mechanism of Alzheimer's disease through protein interaction

Through a complex analysis of protein interactions, researchers from IRB Barcelona and the Joint Programme IRB-BSC have discovered new molecular mechanisms that may be involved in the development of Alzheimer's disease.

17 Dec 2010

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease.

17 Dec 2010

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.

17 Dec 2010

Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

Recordati and Nymox Pharmaceutical Corporation announced today the signing of a European licensing agreement for the development and commercialization of NX-1207, Nymox's Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH).

17 Dec 2010